Spotlight On... UCB wins FDA nod for another epilepsy drug; Onconova sheds staff; and more...

Belgian drugmaker UCB picked up FDA approval for a treatment designed to treat seizures in patients with epilepsy. The drug, brivaracetam, beat out a placebo in cutting back partial-onset seizure frequency and improving response rates in a Phase III trial. It's now approved as an add-on treatment to existing epilepsy therapies, the FDA said. UCB plans to launch it under the brand name Briviact, marking the third approved treatment in the company's banner epilepsy franchise. More

@FierceBiotech: Novartis' blood cancer drug bags a 'breakthrough' tag on the way to FDA filing. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adimab issues a challenge: Use new tech to build a rapid-response R&D platform for infectious diseases. News | Follow @JohnCFierce

@DamianFierce: Voice actors share how they deliver drug ad warnings without sounding, well, scary. More | Follow @DamianFierce

> Pennsylvania biotech Onconova Therapeutics ($ONTX) is laying off 6 staff members, 17% of its payroll, to conserve cash as it works through Phase III development of a once-failed cancer drug. News

> China's nascent biotech scene is on the rise thanks to a boom in funding, the Financial Times reports. Story

> Federal prosecutors said they're having trouble convincing potential witnesses to testify against former biopharma CEO Martin Shkreli. Item

Medical Device News

@FierceMedDev: FDA warns two diagnostics players for marketing unapproved tests. More | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in sales. Article | Follow @EmilyWFierce

> Google's life science arm relocating to South San Francisco. More

> Materialise partners with Mathys to offer 3-D printed, personalized shoulder surgery guides. Story

Pharma News

@FiercePharma: NEJM study finds Actos holds off repeat strokes, heart attacks in insulin-resistant patients. Story | Follow @FiercePharma

@EricPFierce: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. Story | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: U.K. cost gatekeepers say 'show me' to Alexion's new rare disease med Kanuma. Item | Follow @CarlyHFierce

> FDA approves UCB drug for treating epileptic seizures. Story

> Teva offers up concessions for quick EU review of Allergan deal. More

Read more on